According to current data, migraines are one of the most common neurological disorders worldwide and in the United States. Worldwide, migraines affect about 40% of the population (3.1 billion people).

PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength ...

For the full year of 2025, Pfizer posted revenue of 62.6 billion dollars and an adjusted diluted EPS of 3.22 dollars, beating the consensus estimates polled by FactSet, which had anticipated revenue ...

PFE shares fall even after Q4 earnings beat on COVID product declines and muted investor reaction to new obesity drug data.

Pfizer posted adjusted earnings of 66 cents per share, beating the 57 cents forecast by analysts, News.Az reports, citing foreign ...

Discover how rimegepant (Nurtec ODT) works for both migraine treatment and prevention. Learn about the approved age range, ...

Pfizer PFE is set to release its fourth-quarter and full-year 2025 results on Feb. 3, with investor attention focused on oncology sales, which generate more than 28% of total revenues. Key cancer ...

Prices for at least 350 medicines are set to hike this year. That includes COVID-19 treatment Paxlovid, cancer drug Ibrance, and migraine pill Nurtec. CNN reports the increase is up from 250 last year ...

Drugmakers plan to raise U.S. prices on at least 350 branded medications in 2026, including vaccines for COVID-19 and shingles, migraine treatments, and blockbuster cancer drugs, according to data ...

A disabled woman has told Newsweek she is planning to leave the United States with her partner for Canada over concerns President Donald Trump's "One Big Beautiful Bill" (OBBB) may cut Medicaid ...